Consumer confidence leads to H2 warning for Visx:
This article was originally published in Clinica
Laser vision correction company Visx has warned of lower revenues and profits for the second half of the year, due to weak consumer confidence - a major driver of demand for its technology. The Santa Clara, California-based company is expecting second-half EPS of $0.15-0.18, compared with consensus figure of $0.26. For the second quarter, the company had sales of $37m, the same as for the first quarter, but down from the $48m of the previous year's second quarter.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.